- Home
- YSXT vs CGTX Comparison
YSXT vs CGTX Comparison
Compare YSXT & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YSXT | CGTX |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.6M | 158.8M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | YSXT | CGTX |
|---|---|---|
| Price | $2.23 | $1.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.88 |
| AVG Volume (30 Days) | 604.4K | ★ 978.2K |
| Earning Date | 07-31-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $71,452,736.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.81 | ★ N/A |
| Revenue Growth | ★ 22.04 | N/A |
| 52 Week Low | $1.68 | $0.22 |
| 52 Week High | $9.96 | $3.83 |
Technical Indicators
Market Signals| Indicator | YSXT | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.52 | 55.92 |
| Support Level | $2.02 | $1.69 |
| Resistance Level | $2.38 | $1.81 |
| Average True Range (ATR) | 0.27 | 0.13 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 14.71 | 89.19 |
Price Performance
Historical ComparisonAbout YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.